- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04409080
REGN7257 aikuispotilailla, joilla on vaikea aplastinen anemia, joka ei kestä immunosuppressiivista hoitoa tai on uusiutunut
Vaiheen 1/2 tutkimus REGN7257:stä (anti-interleukiini 2 -reseptorialayksikön gamma [IL2RG] monoklonaalinen vasta-aine) potilailla, joilla on vaikea aplastinen anemia, joka ei kestä immunosuppressiivista hoitoa tai uusiutui sen jälkeen
This study is researching an experimental drug called REGN7257 (called "study drug"). The study is focused on patients who have severe aplastic anemia (SAA), a disease of the bone marrow resulting in an impairment of the production of blood cells.
The main purpose of this two-part study (Part A and Part B) is to test how safe and tolerable REGN7257 is in patients with SAA in which other Immunosuppressive therapies (ISTs) have not worked well.
The study is looking at several other research questions to better understand the following properties of REGN7257:
- Side effects that may be experienced by participants taking REGN7257
- How REGN7257 works in the body
- How much REGN7257 is present in blood after dosing
- If REGN7257 works to raise levels of certain blood counts after treatment
- How quickly REGN7257 works to raise levels of certain blood counts
- In patients for whom REGN7257 works to raise levels of certain blood counts after treatment, how many continue to show such a response throughout the study
- If REGN7257 works to lower the number of platelet and red blood cell transfusions needed
- How REGN7257 changes immune cell counts and composition
- How the body reacts to REGN7257 and if it produces proteins that bind to REGN7257 (this would be called the formation of anti-drug antibodies [ADA])
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
The trial was intended to be a Phase 1/2 trial, but no participants were enrolled in Phase 2
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Gyeonggi-do
-
Incheon, Gyeonggi-do, Etelä -Korea, 21565
- Gachon University Gil Hospital
-
-
Seoul Capital Area
-
Seoul, Seoul Capital Area, Etelä -Korea, 03080
- Seoul National University Hospital
-
Seoul, Seoul Capital Area, Etelä -Korea, 06351
- Samsung Medical Center
-
Seoul, Seoul Capital Area, Etelä -Korea, 06591
- The Catholic University of Korea, Seoul St. Marys Hospital
-
Seoul, Seoul Capital Area, Etelä -Korea, 07985
- Ewha Womans University Medical Centre
-
-
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Ranska, 75010
- Hopital Saint-Louis - APHP
-
-
-
-
-
London, Yhdistynyt kuningaskunta, SE5 9RS
- King's College Hospital, London
-
-
West Yorkshire
-
Leeds, West Yorkshire, Yhdistynyt kuningaskunta, LS97TF
- St James's University Hospital
-
-
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44195
- Cleveland Clinic Foundation
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Key Inclusion Criteria:
- Part A: SAA that is IST-refractory or IST-relapsed, as defined in the protocol
- Part B: SAA that is IST-relapsed, as defined in the protocol
- Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a treatment option or has been refused by the patient
- Adequate hepatic and renal function as defined in the protocol
Key Exclusion Criteria:
- Diagnosis of Fanconi anemia or other congenital bone marrow failure syndrome as defined in the protocol
- Evidence of myelodysplastic syndrome as defined in the protocol
- Paroxysmal nocturnal hemoglobinuria (PNH) with evidence of clinically significant hemolysis (eg, treatment indicated) or history of PNH-associated thrombosis
- Treatment with a T cell-depleting agent (eg, ATG or alemtuzumab) within 6 months prior to dosing
- Treatment with a calcineurin inhibitor (eg, cyclosporine) within 4 weeks prior to dosing for patients enrolled in Part A
- Treatment with eltrombopag or investigational thrombopoietin receptor agonist, Granulocyte Colony-Stimulating Factor (G-CSF), or an androgen (eg, danazol), within 2 weeks prior to dosing
- HIV, hepatitis B or hepatitis C positive by serological testing at the screening visit as defined in the protocol
- Active tuberculosis, latent tuberculosis infection (LTBI) or history incompletely-treated tuberculosis or LTBI
- Active infection as defined in the protocol
Note: Other protocol-defined inclusion/ exclusion criteria apply
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part A
Part A: Single ascending dose (SAD) escalation cohorts |
Administered by intravenous (IV) infusion, in Part A and B. |
|
Kokeellinen: Part B
Part B: Multiple REGN7257 dosages. |
Administered by intravenous (IV) infusion, in Part A and B. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of adverse events (AEs)
Aikaikkuna: 12 months post-treatment, approximately 52 weeks
|
Part A |
12 months post-treatment, approximately 52 weeks
|
|
Incidence of serious adverse events (SAEs)
Aikaikkuna: 12 months post-treatment, approximately 52 weeks
|
Part A |
12 months post-treatment, approximately 52 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Aikaikkuna: 12 months post-treatment, approximately 52 weeks
|
Part A |
12 months post-treatment, approximately 52 weeks
|
|
Incidence of serious adverse events (SAEs)
Aikaikkuna: Through the end of study visit, approximately 78 weeks
|
Part B |
Through the end of study visit, approximately 78 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Aikaikkuna: Through the end of study visit, approximately 78 weeks
|
Part B |
Through the end of study visit, approximately 78 weeks
|
|
Overall response rate (ORR)
Aikaikkuna: At 6 months, approximately 26 weeks
|
Part B |
At 6 months, approximately 26 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
ORR
Aikaikkuna: At 3 months, approximately 12 weeks
|
Parts A and B |
At 3 months, approximately 12 weeks
|
|
Complete response (CR)
Aikaikkuna: At 3 months, approximately 12 weeks
|
Parts A and B |
At 3 months, approximately 12 weeks
|
|
Partial response (PR)
Aikaikkuna: At 3 months, approximately 12 weeks
|
Parts A and B |
At 3 months, approximately 12 weeks
|
|
Time to best response
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Time to best response
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Time to first response
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Time to first response
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Any clinical response
Aikaikkuna: Until the end of study, approximately week 52
|
Part A |
Until the end of study, approximately week 52
|
|
Any clinical response
Aikaikkuna: Until the end of study, approximately week 78
|
Part B |
Until the end of study, approximately week 78
|
|
Platelet transfusions per month over time
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Platelet transfusions per month over time
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Red blood cell transfusions per month over time
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Red blood cell transfusions per month over time
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in lymphocyte cell counts
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in lymphocyte cell counts
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in neutrophil cell counts
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in neutrophil cell counts
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in hemoglobin cell counts
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in hemoglobin cell counts
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in reticulocyte cell counts
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in reticulocyte cell counts
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in platelet cell counts
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in platelet cell counts
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in the whole blood immune cell subsets (T cells)
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in the whole blood immune cell subsets (T cells)
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in the whole blood immune cell subsets (B cells)
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in the whole blood immune cell subsets (B cells)
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Changes in the whole blood immune cell subsets [Natural killer (NK) cells]
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Changes in the whole blood immune cell subsets (NK cells)
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Drug concentrations in serum over time
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Drug concentrations in serum over time
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
|
Incidence of treatment-emergent anti-drug antibody (ADA) over time
Aikaikkuna: Up to 12 months
|
Part A |
Up to 12 months
|
|
Incidence of treatment-emergent ADA over time
Aikaikkuna: Up to 18 months
|
Part B |
Up to 18 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Trial Management, Regeneron Pharmaceuticals
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- R7257-RAA-1947
- 2020-002031-29 (EudraCT-numero)
- 2023-508601-24-00 (Rekisterin tunniste: EU CT Number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-jaon aikakehys
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-jaon käyttöoikeuskriteerit
Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- ANALYTIC_CODE
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .